Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Thromboembolic and cardiovascular events after CAR-T cell therapy in multiple myeloma: A propensity-matched real-world analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMohammed AloqailyKAKirti AroraHDHamed Daw

Discussion

Loading...

Member takes

Overview

Real-world analysis shows CAR-T therapy raises VTE risk in multiple myeloma, indicating need for close monitoring.

Key Points

  • To compare the 90-day risk of venous thromboembolism, stroke, and myocardial infarction between CAR-T and non-CAR-T patients with multiple myeloma.
  • Retrospective cohort study using the TriNetX US Collaborative Network for electronic health records.
  • Included adults with multiple myeloma between January 2017 and December 2024.
  • Propensity score matching was employed to create balanced cohorts based on demographics and comorbidities.
  • 171 CAR-T recipients experienced VTE within 90 days compared to 126 controls, with a 36% relative risk increase.
  • Stroke risk was numerically higher but not statistically significant (2.7% vs. 2.3%).
  • Rates of myocardial infarction and acute limb ischemia were similar across both groups.

Cite This Study

Aloqaily et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d078https://doi.org/10.1182/blood-2025-2249
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk of venous and arterial thromboembolic events following CAR-T therapy in relapsed or refractory non-Hodgkin lymphoma: A propensity-matched multicenter analysis.2025
  2. 2Real-world comparative outcomes of CAR-T cell therapy versus pomalidomide-based regimens in relapsed/refractory multiple myeloma: A propensity-matched cohort study2025
  3. 3Influence of Chimeric Antigen Receptor T-Cell Therapy on Fracture Risk of Patients With Multiple Myeloma2025
  4. 4Real-world comparison of CAR T-cell therapy versus bispecific antibodies in relapsed or refractory multiple myeloma2025 · 1 citations
  5. 5CAR-T cell therapy in multiple myeloma in a front-line setting: A systematic review and meta-analysis2025 · 1 citations